Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Blocking cytokines with genes

C H Evans1, S C Ghivizzani, P D Robbins

  • 1Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pennsylvania, USA. cevans@vms.cis.pitt.edu

Journal of Leukocyte Biology
|July 17, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Home delivery for chondrocytes.

Osteoarthritis and cartilage·2025
Same author

How to Cure Rhus Poisoning.

The Homoeopathic physician·2023
Same author

Enthesis: not the same in each localisation - a molecular, histological and biomechanical study.

European cells & materials·2022
Same author

Mechanical and strain behaviour of human Achilles tendon during in vitro testing to failure.

European cells & materials·2022
Same author

Reverse dynamisation: a modern perspective on Stephan Perren's strain theory.

European cells & materials·2021
Same author

Healing of sub-critical femoral osteotomies in mice is unaffected by tacrolimus and deletion of recombination activating gene 1.

European cells & materials·2021
Same journal

Distinct lymphocyte immune signatures to nivolumab and recombinant IL-7 ex vivo in patients with sepsis.

Journal of leukocyte biology·2026
Same journal

Eosinophil Essentials: Identification and Assessment of Activity.

Journal of leukocyte biology·2026
Same journal

Immune cell landscape reveals 5 immune-related subtypes and molecular characteristics with prognostic and therapeutic implications in pan-cancer.

Journal of leukocyte biology·2026
Same journal

High-dimensional single-cell mass cytometry analysis of IL-4 treated human macrophages reveals heterogeneity and a CD206high anticolitic subset.

Journal of leukocyte biology·2026
Same journal

SHIP Blocks (MDP+LPS)-Induced Synergy in Macrophages Independent of Catalytic Activity.

Journal of leukocyte biology·2026
Same journal

CD43: Recent Advances and Emerging Functions.

Journal of leukocyte biology·2026
See all related articles

Gene therapy shows promise for treating rheumatoid arthritis (RA) by targeting key inflammatory cytokines. Early studies and a Phase I clinical trial are evaluating its safety and effectiveness for joint diseases.

Area of Science:

  • Rheumatology
  • Molecular Biology
  • Gene Therapy

Background:

  • Rheumatoid arthritis (RA) pathophysiology involves proinflammatory cytokines like interleukin-1 (IL-1) and tumor necrosis factor alpha.
  • Biological agents blocking these cytokines offer therapeutic benefits in RA models and patients.
  • Limitations in delivering therapeutics to joint tissues necessitate novel treatment strategies like gene therapy.

Purpose of the Study:

  • To explore gene therapy as a treatment for rheumatoid arthritis (RA) and other articular diseases.
  • To evaluate gene delivery approaches and identify effective therapeutic gene products for RA.
  • To assess the safety and feasibility of gene therapy for RA through a Phase I clinical trial.

Main Methods:

  • Investigating local gene delivery to synovial cells (in vivo and ex vivo) and systemic administration of gene vectors.

Related Experiment Videos

  • Identifying and testing therapeutic gene products, including IL-1 receptor antagonist, soluble IL-1 receptor I, soluble tumor necrosis factor receptor II, viral IL-10, and transforming growth factor beta.
  • Conducting a Phase I clinical trial to evaluate safety and feasibility.

    • Main Results:

    • Significant progress in evaluating gene delivery methods for RA treatment.
    • Demonstrated therapeutic efficacy of various gene products in animal models of RA.
    • Successful initiation of a Phase I clinical trial based on promising laboratory findings.

    Conclusions:

    • Gene therapy presents a viable approach to overcome challenges in RA treatment delivery.
    • Further research and clinical trials are warranted to establish gene therapy's role in managing RA.
    • The development of targeted gene therapies holds potential for improved outcomes in articular diseases.